Abstract 54P
Background
Disialoganglioside (GD2) is a glycolipid antigen highly expressed in several solid tumors. A chimeric antigen receptor (CAR)-T cell targeting GD2 has been developed and recently showed promising results in clinical trials for neuroblastoma. Previous generations of aGD2-CAR-T cells belong to second—and third-generation CARs, which harbor one and two costimulatory domains within their CAR structures. Incorporation of co-stimulatory domains may help improve CAR T-cell functions. We aim to validate whether incorporating three costimulatory domains within fourth-generation CAR (CAR4) can improve antitumor efficiency against GD2-positive tumors in vitro.
Methods
A fourth-generation CAR containing humanized scFv-GD2, hu3F8, and three costimulatory domains composed of CD28, 4-1BB, and CD27 linked to a CD3 zeta was produced in primary human T cells by using a lentiviral vector system. Two versions of third-generation CAR were also maced (CAR3.1 and CAR3.2 containing co-stimulatory parts of CD28/BB or CD28/CD27, respectively), linked to a CD3z signaling domain. Antitumor activity, CAR-T cell proliferation, and cytokine production were compared between CAR3 and CAR4-T cells against human neuroblastoma and retinoblastoma cell lines.
Results
In vitro, co-culture assays showed that aGD2-CAR4-T exerted superior anti-tumor efficiency than aGD2-CAR3-T cells for killing neuroblastoma. In contrast, these aGD2-CAR-T did not destroy a normal retinal epithelial cell that lacks GD2 expression. However, upon long-term co-culture for 72 h, anti-GD2-CAR4-T showed more excellent cytolytic activities than CAR3-T cells. Interestingly, cytokine production levels, IFN-γ and TNF-α, secreted from anti-GD2-CAR4-T cells were slightly lower than those from CAR3-T cells. We observed that CAR3.2 containing CD27 (CD28/CD27z) had the highest proliferative capacity upon antigen engagement.
Conclusions
Our fourth-generation CAR T-cells targeting GD2 showed superior cytolytic activities than third-generation CAR T-cells against GD2-positive tumor cells in vitro. Anti-GD2-CAR4-T cells will be a promising therapeutic strategy for GD2-positive cancers.
Legal entity responsible for the study
The authors.
Funding
The Office of National Higher Education Science Research and Innovation Policy Council (NXPO) by Program Management Unit-Competitiveness (PMU-C) (grant no. C10F630063).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract